Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 12, Issue 4, 2014

In the last few decades, popularity of coronary interventions has risen rapidly. Widespread use of coronary stents and high number of patients with atherosclerosis made the stents the focus of attention by the industry. This has led the stent technology to evolve rapidly. The aim of this review is to outline the evolution of coronary stents and the stent components in the timeline. Pharmacogenomics, personalized medicine and co Read More

Pancreatic cancer is the fourth leading cause of death from cancer. Maximizing therapeutic benefit relies on careful review of inter-individual characteristics. Current and future pharmacogenomics principles may assist in this personal approach and may eventually become widespread. Until then, providers must rely on the available data that might be considered most applicable at the current time. Systemic treatment o Read More

Methadone, a synthetic opioid, is mainly used as an analgesic and a maintenance antiaddictive and reductive preparation in the treatment of opioid dependence. A better understanding of the factors underlying individual responses to methadone is required in order to improve treatment individualization, thereby potentially leading to better clinical efficacy. Evidence now suggests that pharmacogenetics has a role in the ef Read More

The identification of genetic factors that influence drug responses often focuses on genes whose variants are predicted to alter pharmacokinetic and/or pharmacodynamic parameters—leading to an increased risk of drug toxicity or therapeutic failure. In this study, we selected 48 genes identified as “Very Important Pharmacogenes (VIPs)” by the PharmGKB database, and developed a fivefeature Structural Disturbance S Read More

The renin-angiotensin system (RAS) genes polymorphism have been associated with blood pressure (BP) response to antihypertensives drugs and may also influence the variability in visit-tovisit BP. Here we have investigated the association of RAS gene polymorphism with response to three classes of antihypertensive drugs (atenolol, amlodipine and enalapril) and also with genetic factor which may influence the variability in Read More

The present study is part of the genetic mapping of Indonesia focusing on drug metabolizing enzymes, which started with the Buginese population of Makassar, South Sulawesi. The two CYP450 gene subfamilies, i.e. CYP2C9 and CYP2C19 are of interest as they exhibit wide inter-individual variation in expression, which influence the drug metabolism capacity. The CYP2C9 alleles of interest in this study were CYP2C9*2 and *3 Read More

Tyrosine kinase inhibitors (TKI) have significantly improved the prognosis for chronic myelogenous leukemia (CML) patients. Several mechanisms of resistance have been identified, however. BCR-ABL-dependent resistance is the most frequently occurring, usually as mutations preventing therapeutic drug interaction. This study addresses a mechanism of resistance observed in the absence of mutations. During TKI challen Read More